Eunice Chang

Eunice Chang

Auto-generated profile, based on publicly available information

Eunice Chang

ADVI Health, LLC, Washington, DC 20004, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
WPWilliam H. Parker
William H. Parker
DFDiane ScD Feskanich
Diane ScD Feskanich
MBMichael S. Md Broder
Michael S. Md Broder
ECEunice Chang
Eunice Chang
DSDonna Shoupe
Donna Shoupe
JMJoAnn E. MD Manson
JoAnn E. MD Manson
OBJECTIVE: To report long-term mortality after oophorectomy or ovarian conservation at the time of hysterectomy in subgroups of women based on age at the time of surgery, use of estrogen therapy, presence of risk factors for coronary heart disease, and length of follow-up. METHODS: This was a prospective cohort study of 30,117 Nurses' Health Study participants undergoing hysterectomy for benign disease. Multivariable adjusted hazard ratios for death from coronary heart disease, stroke, breast cancer, epithelial ovarian cancer, lung cancer, colorectal cancer, total cancer, and all causes were determined comparing bilateral oophorectomy (n=16,914) with ovarian conservation (n=13,203). RESULTS: Over 28 years of follow-up, 16.8% of women with hysterectomy and bilateral oophorectomy died from all causes compared with 13.3% of women who had ovarian conservation (hazard ratio 1.13, 95% confidence interval 1.06–1.21). Oophorectomy was associated with a lower risk of death from ovarian cancer (four women with oophorectomy compared with 44 women with ovarian conservation) and, before age 47.5 years, a lower risk of death from breast cancer. However, at no age was oophorectomy associated with a lower risk of other cause-specific or all-cause mortality. For women younger than 50 years at the time of hysterectomy, bilateral oophorectomy was associated with significantly increased mortality in women who had never used estrogen therapy but not in past and current users: assuming a 35-year lifespan after oophorectomy: number needed to harm for all-cause death=8, coronary heart disease death=33, and lung cancer death=50. CONCLUSIONS: Bilateral oophorectomy is associated with increased mortality in women aged younger than 50 years who never used estrogen therapy and at no age is oophorectomy associated with increased survival. LEVEL OF EVIDENCE: I

1 February 2014 in Epilepsy & Behavior
Verified
Journal Article
Closed access
JCJoyce A. Cramer
Joyce A. Cramer
ZWZhixiao J. Wang
Zhixiao J. Wang
ECEunice Chang
Eunice Chang
APAnnette Powers
Annette Powers
RCRonda Copher
Ronda Copher
MBMichael S. Broder
Michael S. Broder

5 January 2016 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
KRKarina Raimundo
Karina Raimundo
ECEunice Chang
Eunice Chang
MBMichael S. Broder
Michael S. Broder
KAKimberly Alexander
Kimberly Alexander
JZJames Zazzali
James Zazzali
JSJeffrey J. Swigris
Jeffrey J. Swigris
Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a variable course. Not uncommonly, IPF patients are hospitalized for respiratory-related causes, including disease worsening. This study aimed to characterize the prevalence, and economic and health care burden of IPF. Retrospective insurance claims data collected yearly between January 1, 2009 and December 31, 2011, were used to determine prevalence and calculate all-cause and respiratory-related resource utilization and costs. Patients had at least one inpatient claim or two outpatient claims for IPF (ICD-9-CM code 516.3). Results for health care burden are reported for the 2011 cohort (similar findings in 2009–2010). Costs are reported in 2011 US dollars ($). Patients with IPF had a mean age of 69.8–71.3 years. Overall prevalence for IPF was 28.8, 28.1 and 19.8 per 100,000 insured persons in 2009, 2010 and 2011. In each year, prevalence increased with age. In 2011, 37.7 % of patients were hospitalized at least once for any cause; 19.5 % for respiratory-related reasons. Also in 2011, the mean number of all-cause outpatient visits and respiratory-related office visits was 18.5 and 5.7 per patient, respectively. All-cause health care costs in 2011 were $59,379 per patient; 36.6 % of costs ($21,732) were respiratory related. The prevalence of IPF in this claims database increased with age, with a notable increase in those over 65 years. IPF is associated with a large economic and health care burden. Additional research is needed to determine how such burden might be reduced.

1 March 2014 in Epilepsy & Behavior
Verified
Journal Article
Closed access
JCJoyce A. Cramer
Joyce A. Cramer
ZWZhixiao J. Wang
Zhixiao J. Wang
ECEunice Chang
Eunice Chang
APAnnette Powers
Annette Powers
RCRonda Copher
Ronda Copher
MBMichael S. Broder
Michael S. Broder

22 May 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
JMJoshua J. Mooney
Joshua J. Mooney
KRKarina Raimundo
Karina Raimundo
ECEunice Chang
Eunice Chang
MBMichael S. Broder
Michael S. Broder
Idiopathic pulmonary fibrosis (IPF) is associated with increased risk of respiratory-related hospitalizations. Studies suggest mechanical ventilation (MV) use in IPF does not improve outcomes and guidelines recommend against its general use. Our objective was to investigate MV use and association with cost and mortality in IPF. This retrospective study, using a nationwide sample, included claims with IPF (ICD-9-CM: 516.3) in 2009–2011 and principal respiratory disease diagnosis (ICD-9-CM: 460–519); excluding lung transplant. Regression models were used to determine predictors of MV and association with cost, LOS, and mortality. Domain analysis was used to account for use of subpopulation. Costs were adjusted to 2011. Data on patient severity not available. Twenty two thousand three hundred fifty non-transplant IPF patients were admitted with principal respiratory disease diagnosis: Mean age 70.0 (SD 13.9), 49.1% female, mean LOS 7.4 (SD 8.2). MV was used in 11.4% of patients with a non-significant decline over time. In regression models, MV was associated with an increased stay of 9.78 days (95% CI 8.38–11.18) and increased cost of $36,583 (95% CI $32,021–41,147). MV users had significantly increased mortality (OR 15.55, 95% CI 12.13–19.95) versus nonusers. Mechanical ventilation use has not significantly changed over time and is mostly used in younger patients and those admitted for non-IPF respiratory conditions. MV was associated with a 4-fold admission cost increase ($49,924 versus $11,742) and a 7-fold mortality increase (56% versus 7.5%), although patients who receive MV may differ from those who do not. Advances in treatment and decision aids are needed to improve outcomes in IPF.

9 March 2017 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
JCJohn D. Carmichael
John D. Carmichael
MBMichael S. Broder
Michael S. Broder
DCDasha Cherepanov
Dasha Cherepanov
ECEunice Chang
Eunice Chang
AMAdam Mamelak
Adam Mamelak
VBVivien Bonert
Vivien Bonert
The study aim was to estimate the proportion of acromegaly patients with various comorbidities and to determine if biochemical control was associated with reduced proportion of cardiovascular risk factors. Data were from a single-center acromegaly registry. Study patients were followed for ≥12 months after initial treatment. Study period was from first to last insulin-like growth factor-I and growth hormone tests. Of 121 patients, 55% were female. Mean age at diagnosis was 42.4 (SD: 15.0). Mean study period was 8.8 (SD: 7.2) years. Macroadenomas were observed in 93 of 106 patients (87.7%), and microadenomas in 13 (12.3%). Initial treatment was surgery in 104 patients (86%), pharmacotherapy in 16 (13.2%), and radiation therapy in 1 (0.8%). Of 120 patients, 79 (65.8%) achieved control during the study period. New onset comorbidities (reported 6 months after study start) were uncommon (8 years of treatment, demonstrating the difficulty of achieving control in some patients.